Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 long-term open-label study in moderate-to-severe plaque psoriasis
jRCT2031240413Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of zasocitinib in plaque psoriasis (2 cohorts), sponsored by Takeda. Primary endpoint: Number of participants with treatment-emergent adverse events and serious adverse events. Started Sep 2024; status: active, not recruiting.
02
Drugs
zasocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2031240413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240413.